Kenvue Stock Recoups Losses After Trump Links Tylenol to Autism

Kenvue (KVUE) shares rebounded significantly, recovering almost 60% of losses, after President Trump's comments linking Tylenol to autism, as the subsequent administration policy was perceived as "better-than-feared" by investors, avoiding an outright ban. The new guidance will involve updated warning labels and a public service campaign advising pregnant women on Tylenol usage, which Citi analysts estimate could still reduce Kenvue's profit by $40M-$50M if Tylenol sales, representing 10% of revenue, drop by 10%.

Analysis

Kenvue (KVUE) shares experienced significant event-driven volatility, initially declining over 7% before rebounding to recover almost 60% of those losses. This price action reflects a classic 'better-than-feared' scenario, as investors had priced in the potential for severe regulatory action, such as an outright ban on Tylenol, following comments from President Trump. The administration's actual policy was far less stringent, focusing on updated warning labels and a public service campaign, with its own fact sheet noting that a causal link between acetaminophen and autism is not definitively established. Tylenol is a material product for Kenvue, estimated by Citi to represent about 10% of sales and 12-15% of operating profit. While the acute regulatory risk has subsided, a forward-looking risk to consumer demand remains. Citi analysts project that a 10% drop in Tylenol sales could reduce Kenvue's profit by $40 million to $50 million. This potential headwind is partially counterbalanced by statements from medical bodies like the American College of Obstetricians and Gynecologists, which affirmed the safety of acetaminophen and noted the lack of safe alternatives for fever in pregnant women, creating a divergence between political rhetoric and scientific consensus.

Key Decisions for Investors

• While the immediate regulatory threat has passed, investors should now focus on the longer-term risk to Tylenol's brand perception and consumer demand stemming from the new government guidance and public service campaigns.
• It is prudent to quantify the potential financial impact, noting that a 10% decline in Tylenol sales—which account for 10% of revenue and 12-15% of operating profit—could reduce Kenvue's profit by an estimated $40 million to $50 million.
• Monitor the company's upcoming quarterly reports for any weakness in the self-care segment and management's discussion of Tylenol consumption trends to gauge the real-world effect of this development.